STAT+: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s from Cassava Sciences.

The company said Thursday that a preliminary analysis of a small clinical trial showed its drug, called simufilam, improved the cognition of patients with Alzheimer’s disease — a benefit that no other treatment for Alzheimer’s has ever shown.

Continue to STAT+ to read the full story…

STAT+: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top